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Abstract
Background
The blood to anticoagulant ratio is standardized according to the physiological calcium con-
centration in blood samples conventionally used for hemostasis testing. Specifically, one
fixed volume of 0.109 mmol/L sodium citrate is added to 9 volumes of blood. Since little is
known about the impact of hypercalcemia on the calcium-binding capacity of citrate, this
study was planned to investigate the effect of experimental hypercalcemia on routine hemo-
stasis testing.
Methods
Fifteen pooled citrated plasmas with matching lithium-heparin pooled plasma from patients
with different values of prothrombin time (PT) were divided in three aliquots of 0.6mL each.
The first paired aliquots of both citrate and lithium-heparin plasma were supplemented with
60μL of saline, the second paired aliquots with 30μL of saline and 30μL of calcium chloride
and the third paired aliquots with 60μL of calcium chloride. Total and ionized calcium was
measured in all aliquots of citrate and lithium-heparin plasma, whereas PT, activated partial
thromboplastin time (APTT) and fibrinogen were measured in citrate plasma aliquots.
Results
Total calcium concentration gradually increased in both lithium-heparin and citrate plasma
aliquots 2 and 3 compared to baseline aliquot 1. The concentration of ionized calcium also
gradually increased in lithium-heparin plasma aliquots 2 and 3, whereas it remained immea-
surable (i.e., <0.10 mmol/L) in all citrate plasma aliquots. No significant differences were
observed for values of PT, APTT and fibrinogen in citrate plasma aliquots 2 and 3 compared
to the baseline aliquot 1, with a mean bias was always comprised within the desirable quality
specifications derived from biological variability data.
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Conclusion
Hypercalcemia, up to severe hypercalcemia does not generate significant bias in results of
first-line coagulations tests, so that hypothetical consideration of adjusting citrate-blood ratio
is unjustified in hypercalcemic patients.
Introduction
Laboratory testing is vital for screening, diagnosing and monitoring treatment related to
hemostasis disturbances, as associated with both thrombotic and bleeding risk [1,2]. Coagula-
tion tests are usually classified according a conventional hierarchy of complexity, entailing
first-line (i.e., screening), second-line (i.e., diagnostic) and third-line tests, the last of which are
usually performed to help defining the specific nature and severity of an underlying hemostatic
disorder [3]. Due to the crucial role of haemostasis testing in diagnosing and managing hemo-
stasis disturbances, a high degree of accuracy must be assured throughout the total testing pro-
cess, i.e., from sample collection to testing and clinical interpretation of data [4–7].
Like other areas of laboratory medicine (in particular, clinical chemistry) there are many
preanalytical confounders to accuracy, if not appropriately controlled for or identified. Thus,
inaccurate data of coagulation tests may be due to many preanalytical problems, the most
important of which include incorrect sample type and potential contamination [8]. As regards
to haematocrit, increased values, typically above 0.55 (i.e., >55%), may substantially impair
the ratio of blood to citrate in plasma, resulting in severe derangements of coagulation test
results. Importantly, the amount of citrate that remains free after ionized calcium in the plasma
sample has been bound may then also bind to the same ion upon sample recalcification and
before performing coagulation tests, so that any variation in the conventional ratio between
calcium and citrate may impair the clotting times of many hemostasis tests [9]. To overcome
the problem of high hematocrit, for example, the Clinical and Laboratory Standards Institute
(CLSI) document H21-A4 contains specific instructions that citrate concentration should be
adjusted for haematocrit values above 0.55 [10], and this can be accomplished by using a sim-
ple formula such as: [residual volume of citrate in the tube] = [100-hematocrit][sample vol-
ume]/[595-hematocrit]. This background highlights that biological factors impairing the
standardized blood to citrate ratio may ultimately jeopardize the reliability of coagulation test
results. Among these factors, therefore, hypercalcemia may also play an important role.
The current CLSI guidelines recommend that blood should be preferably drawn into evacu-
ated blood tubes containing 0.105–0.109 mol/L (i.e., 3.2%) buffered sodium citrate, and that
an accurate blood to anticoagulant ratio of 9:1 should be fulfilled in order to maintain a stan-
dardized ratio between the binding capacity of this anticoagulant and the calcium present in
the blood sample [10]. The plasma and serum concentration of total calcium is normally com-
prised between 2.0–2.5 mmol/L, whereas that of ionized calcium is normally comprised
between 1.0–1.4 mmol/L. Modest hypercalcemia is then diagnosed when total calcium in
plasma or serum is 3.0–3.5 mmol/L, whereas severe hypercalcemia is diagnosed when total cal-
cium in plasma or serum is>3.5 mmol/L [11]. It is feasible that the excess of calcium present
in the blood of hypercalcemic patients may not be completely neutralized by the standardized
concentration of citrate in the blood tube, potentially leading to spurious alternation of clot-
ting times. Interestingly, nearly 35 years ago, Small and Mallette reported the case of undue
clotting of a complete blood cell count blood tube anticoagulated with EDTA, due to the pres-
ence of severe hypercalcemia [12], thus confirming that an excess of calcium in blood may
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overwhelm the binding capacity of conventional anticoagulant additives with calcium-binding
capacity. However, no studies have specifically assessed the potential impact of hypercalcemia
on coagulation testing to the best of our knowledge. Therefore, this original investigation
planned to investigate the impact of experimental hypercalcemia on first-line, routine hemo-
stasis testing, encompassing performance of prothrombin time (PT), activated partial throm-
boplastin time (APTT) and fibrinogen.
Materials and methods
A total number of 30 routine coagulation samples were identified according to their PT value,
and concomitant availability of a paired lithium-heparin specimen referred for routine cal-
cium measurement. The samples were selected as follows: 10 routine samples with values of
PT comprised between 0.97–1.09 (set A; routine ‘normal haemostasis’ samples), 10 samples
from patients on oral anticoagulant therapy (OAT) with values of PT comprised between
1.50–2.50 (set B; modestly ‘abnormal’ or ‘anticoagulated’ samples) and 10 samples of patients
on OAT with values of PT comprised between 2.5–3.7 (set C; highly abnormal or anticoagu-
lated samples). These were selected in order to assess any potential effect of hypercalcemia on
both normal and abnormal samples, including patients being monitored for therapy, and
where an effect might affect their clinical management. All routine samples were collected in
evacuated blood tubes containing either 0.109 mmol/L buffered sodium citrate (citrate plasma;
Vacutest Kima, Padova, Italy) or lithium-heparin (lithium-heparin plasma; Vacutest Kima)
and were then separated by standard centrifugation at 1500 g per 10 min at room temperature.
To obtain the minimum amount of plasma volume necessary for testing, 1.0 mL of two cit-
rate patient samples of each set (A; B; C) were pooled to obtain a final volume of 2.0 mL each,
thus producing fifteen separate pooled citrate plasmas, five for each set. Each citrate plasma
pool was then used to prepare 3 identical aliquots (aliquots 1, 2 and 3) of exactly 0.6 mL. Simi-
larly, 1.0 mL of two lithium-heparin patient samples of each set (A; B; C), exactly matching the
citrate plasma specimens used for the previous procedure, were also pooled to obtain a final
volume of 2.0 mL, thus producing fifteen lithium-heparin plasmas, five for each set. According
to this procedure, then, each lithium-heparin plasma pool was made from the same patient
plasmas used to obtain the citrate plasma pools. Each lithium-heparin plasma pool was then
used to prepare 3 identical aliquots (aliquots 1, 2 and 3) of exactly 0.6 mL, as per the citrate
plasma aliquots, thus producing matched pairs. A stock solution of 0.02 mol/L calcium chlo-
ride (HemosIL 0.020 M; Instrumentation Laboratory; Bedford, MA, USA) was used to experi-
mentally increase the calcium concentration of citrate and lithium-heparin plasma. Briefly,
60 μL of saline was added to each aliquot of citrate plasma and lithium-heparin plasma labelled
as aliquot 1, 30 μL of saline plus 30 μL of calcium chloride solution were added to each aliquot
of citrate plasma and lithium-heparin plasma labelled as aliquot 2, and 60 μL of calcium chlo-
ride solution were added to each aliquot of citrate plasma and lithium-heparin plasma labelled
as aliquot 3.
The PT, APTT and fibrinogen were measured on plasma citrate aliquots 1, 2 and 3 using an
ACL TOP 700 coagulation analyzer (Instrumentation Laboratory), with RecombiPlasTin
(Instrumentation Laboratory), SynthASil (Instrumentation Laboratory) and Fibrinogen-CXL
(Instrumentation Laboratory), respectively. The analytical performance of these tests has been
described elsewhere [13]. The normal PT ratio was calculated as for current indications, on a
population of 120 ostensibly healthy blood donors. More specifically, the PT value in seconds
of each subject was divided by the mean normal PT in seconds (MNPT; the geometric mean
PT value of 20 healthy subjects). The reference range was then calculated to comprise the 95%
confidence interval of the population. Total calcium was measured on both citrate and
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lithium-heparin aliquots 1, 2 and 3 using a Cobas 6000 clinical chemistry analyzer (Roche
Diagnostics GmbH, Penzberg, Germany), with the 5-Methyl-5’-nitro BAPTA reagent. Ionized
calcium was assayed on both citrate and lithium-heparin aliquots 1, 2 and 3 on GEM Premier
4000 (Instrumentation Laboratory), which uses a calcium-selective electrode. As claimed by
the manufacturer, the reportable range of ionized calcium is comprised between 0.10–5.00
mmol/L. All tests were performed in duplicate (results were finally averaged), within 3 hours
of sample arrival in the laboratory.
The results of testing are shown as mean and standard deviation (SD), and were analyzed
with paired Student’s T-test, Spearman’s correlation and Bland and Altman plots. Signifi-
cance of percentage variation of coagulation testing in hyperalcemic plasmas was compared
with the current desirable quality specifications for bias derived from intra- and inter-indi-
vidual biologic variation (PT, 2.0%; APTT, 2.3%; fibrinogen, 4.8%) [14]. The statistical analy-
sis was performed using the statistical software Analyse-it (Analyse-it Software Ltd, Leeds,
UK). The study was carried out in accordance with the Declaration of Helsinki and was
approved by the Institutional Review Board of the University Hospital of Verona (Approval
number: 970CESC). In accordance with ‘quality assurance studies’, informed consent was
deemed as unnecessary, since the entire study was performed using residual plasma (i.e., rou-
tine samples referred for hemostasis and clinical chemistry testing, used for the experiments
after routine testing had been completed, and which would otherwise be discarded).
Results
The main results of this study are shown in Table 1.
As predictable, the total calcium concentration gradually increased in lithium-heparin and
citrate plasma aliquots 2 (lithium-heparin plasma: 3.10±0.10 mmol/L; modest hypercalcemia)
and 3 (lithium-heparin plasma: 4.12±0.16 mmol/L; severe hypercalcemia) compared to the
baseline aliquot 1 (lithium-heparin plasma: 2.18±0.09 mmol/L; normal calcium concentra-
tion). A highly significant correlation was found between total calcium measured in all lith-
ium-heparin and all citrate plasma aliquots (r = 0.991; p<0.001) (Fig 1).
The concentration of ionized calcium also gradually and substantially increased in lithium-
heparin plasma aliquots 2 (1.29±0.09 mmol/L) and 3 (1.60±1.13 mmol/L) compared to the
baseline aliquot 1 (0.87±0.03 mmol/L), whereas it remained always not measurable (i.e., <0.10
mmol/L) in all citrate plasma aliquots 1, 2 and 3. A highly significant correlation was also
observed between total and ionized calcium measured in all lithium-heparin aliquots
(r = 0.941; p<0.001) (Fig 1). As regards to results of coagulation testing, no significant
Table 1. Effect of experimental hypercalcemia on Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) and fibrinogen. Results
are shown as mean and standard deviation (SD).
Parameter Aliquot 1 Aliquot 2 Aliquot 3
Value Value p* Value p*
Total calcium in lithium-heparin plasma (mmol/L) 2.18±0.09 3.10±0.10 <0.001 4.12±0.16 <0.001
Ionized calcium in lithium-heparin plasma (mmol/L) 0.87±0.03 1.29±0.09 <0.001 1.60±0.13 <0.001
Total calcium in citrate plasma (mmol/L) 1.89±0.08 2.84±0.09 <0.001 3.79±0.08 <0.001
Ionized calcium in citrate plasma (mmol/L) <0.10 <0.10 - <0.10 -
PT (sec) 22.3±10.1 22.3±10.0 0.470 22.4±10.1 0.154
APTT (sec) 31.6±5.6 31.5±5.6 0.127 31.3±6.6 0.141
Fibrinogen (g/L) 3.93±0.79 3.92±0.92 0.459 3.99±0.86 0.170
* versus aliquot 1
https://doi.org/10.1371/journal.pone.0175094.t001
Experimental hypercalcemia on routine haemostasis testing
PLOS ONE | https://doi.org/10.1371/journal.pone.0175094 March 31, 2017 4 / 8
differences were seen for the values of PT, APTT and fibrinogen in citrate plasma aliquots 2
and 3 compared to the baseline aliquot 1 (Table 1). Accordingly, the mean bias estimated with
Bland and Altman plot analyses was always comprised within the desirable quality specifica-
tions (Fig 2).
More specifically, when compared to the baseline aliquot 1, the bias was 0.3% (95% CI,
-0.5% to 1.0%) in aliquot 2 and 0.6% (95% CI, -0.2% to 1.4%) in aliquot 3 for PT, -0.3% (95%
CI, -1.0% to 0.3%) in aliquot 2 and -1.7% (95% CI, -4.0% to 0.6%) in aliquot 3 for APTT, -0.8%
(95% CI, -3.5% to 2.0%) in aliquot 2 and 1.3% (95% CI; -2.0% to 4.6%) in aliquot 3 for fibrino-
gen, respectively.
Discussion
The first evidence that a concentration of 0.01 mmol/L of sodium citrate may be sufficient to
inhibit the coagulation process by neutralizing a physiological concentration of ionized cal-
cium was provided by Quick and Stefanini nearly 70 years ago [15]. Since then, only few stud-
ies have been published regarding the potential impact of hypercalcemia on citrate-binding
capacity and hemostasis testing. More than 40 years ago, Hilgard evaluated the effect of experi-
mental hypercalcemia on blood coagulation in mice [16]. Hypercalcemia was induced by
transplanting solid Walker 256 cancer and intraperitoneally injecting calcium gluconate. The
effect on blood coagulation was then assessed by measuring whole blood clotting times in
polystyrene and glass test tubes. A significant shortening of clotting times was observed at
serum calcium concentrations between 5.1–5.7 mmol/L, thus being virtually incompatible
with life, which was also found to be more pronounced in polystyrene (-44%) than in glass
(-25%) tubes. Additional data suggesting that calcium may actually influence blood coagula-
tion was conveyed by Bristow et al, who evaluated the impact of calcium supplements on
thromboelastography (TEG) in post-menopausal women [17]. Interestingly, an increase of
coagulation index was only noticed 4 h after ingestion of 1 g of calcium citrate, yielding a sig-
nificant shortening of the time of clot initiation, thus reflecting a greater tendency toward
Fig 1. Spearman’s correlation between total calcium in lithium-heparin plasma and total calcium in citrate plasma or ionized calcium in
lithium-heparin plasma.
https://doi.org/10.1371/journal.pone.0175094.g001
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hypercoagulability. No effects were instead observed at other different time points (i.e., 2, 6
and 8 hours).
The use of buffered sodium citrate anticoagulation for blood in laboratory diagnostics is
unavoidable, since this additive generates a stable source of both blood and plasma then used
for many haemostasis tests. As mentioned, the volume of citrate in evacuated blood tubes is
standardized according to a constant volume of blood (typically 1:9), but this standard does
Fig 2. Bland and Altman plots of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) and fibrinogen in paired
aliquots of citrate plasma with increasing amount of calcium. The continuous and dotted horizontal lines indicate the mean bias and the
95% confidence interval (95% CI).
https://doi.org/10.1371/journal.pone.0175094.g002
Experimental hypercalcemia on routine haemostasis testing
PLOS ONE | https://doi.org/10.1371/journal.pone.0175094 March 31, 2017 6 / 8
not consider potential changes to the concentration of calcium in human blood, which may be
occasionally increased, for example in patients with hypercalcemia, which may in turn arise
for many reasons (e.g., hyperparathyroidism, cancer, granulomatous diseases, immobilization,
increased intake or absorption and use of thiazide diuretics). Despite recognition that high
hematocrit or insufficient filling of evacuated blood tubes are frequent causes of spurious pro-
longation of both PT and APTT for decades [18], very little attention has been given to the fact
that calcium in blood or plasma is actually the main target of citrate anticoagulation, so that an
excess of this ion may overwhelm the calcium-binding capacity of citrate. The results of our
study clearly attest, however, that neither mild or severe hypercalcemia generate a substantial
bias in test results of PT and APTT, so that the use of corrective formulas for adjusting the
ratio between blood and citrate in patients with calcium concentration exceeding the upper
limit of the normal range (i.e., >2.5–2.6 mmol/L) is neither necessary or advisable. Notably,
the concentration of ionized calcium in all citrate aliquots in our study, including those with a
corresponding concentration of 1.60±0.13 mmol/L in lithium-heparin plasma (i.e., aliquots 3),
were always immeasurable (i.e., <0.10 mmol/L), thus suggesting that the actual concentration
of 0.109 mol/L buffered sodium citrate, as conventionally used for anticoagulation of plasma
for coagulation studies, is sufficient to sequestrate all the excess of ionized calcium even in
hypercalcemic patients, displaying total and ionized calcium concentrations as high as 4.1
mmol/L and 1.6 mmol/L, respectively. This is consistent with previous data showing that the
probability of clot formation is extremely unlikely below a concentration of 0.23 mmol/L of
ionized calcium [19], whereas normal clotting in recalcified plasma can only be attained in cit-
rate plasma samples in which the concentration of ionized calcium exceeds 0.56 mmol/L [20].
Despite the limited number of samples tested and the in vitro nature of this study, we hence
conclude that hypercalcemia, inclusive of severe hypercalcemia (i.e., total calcium values>3.0
mmol/L and ionized calcium values>1.40 mmol/L) does not generate a significant bias in
results of first-line, routine coagulations tests.
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